Roche Sequencing Solutions, Inc. entered into an agreement to acquire Global license of double-stranded DNA from Codexis, Inc. on February 26, 2024. Under the terms of the deal, Codexis will receive upfront and technical milestone payments.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.37 USD | -0.30% | +6.35% | +9.84% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.84% | 238M | |
+45.07% | 54.63B | |
-7.02% | 39.92B | |
+37.07% | 38.82B | |
+12.74% | 26.86B | |
-11.17% | 26.22B | |
-22.12% | 18.78B | |
+24.80% | 12.21B | |
-0.05% | 12.16B | |
+24.94% | 11.94B |
- Stock Market
- Equities
- CDXS Stock
- News Codexis, Inc.
- Roche Sequencing Solutions, Inc. entered into an agreement to acquire Global license of double-stranded DNA from Codexis, Inc.